. 2019 Oct 10;3:100046. doi: 10.1016/j.jvacx.2019.100046

Table 1.

Assessment of the protection induced by the indicated treatments against morbidity and mortality after intravenous S. suis serotype 9 challenge.

Immunization antigen	Morbidity	Mortality	Mean clinical score^e (SD)	Clinical signs			Max. body temperature (°C)
Immunization antigen	Morbidity		Mean clinical score^e (SD)	CNS^a	Lameness	no feed intakee	<40	≥40 and ≤40.2	>40.2
placebo	8/9	8^b/9	21 (8.1)	4/9	3^c/9	4(6)^d/9	1^d/9	0^d/9	6^d/9
rIde_Ssuis	8/9	0/9	6 (3.9)	0/9	4/9	1/9	1/9	1/9	7/9

Signs of central nervous system (CNS) dysfunction such as convulsions and opisthotonus.

One placebo-treated piglet showed central nervous system dysfunction and reached a score of 25 on the last day of the experiment.

Three additional piglets became recumbent.

Two piglets died a few hours after experimental infection prior to the first feeding and measurement of body temperature.

For the detailed clinical scoring system see Table S1.